The research, led by Angang Ding and Jinye Cao, who contributed equally, along with colleagues including Huan Lv, Jiaxin Zuo, Huihong Zhou and Ping Xiong, set out with a deceptively simple objective. Calcifications appear on ultrasound as bright, echogenic foci that reflect sound waves strongly, and they show up in a wide variety of tumors. But until now, there has been no agreed framework for classifying what those deposits look like in salivary gland lesions, and no clear answer to the question that matters most in the clinic: do certain calcification patterns predict malignancy? The team systematically catalogued clinical characteristics, lesion size and calcification morphology across their cohort, then tested whether the patterns differed between benign and malignant tumors.

The answer, distilled from their analysis, is a four-part classification. The researchers sorted calcifications into distinct ultrasonographic types: scattered microcalcifications, in which tiny bright specks are distributed loosely through the lesion; clustered microcalcifications, where similar small deposits group tightly together; macrocalcifications, which are larger, coarser calcium bodies; and irregular calcifications, deposits with jagged, non-uniform contours that defy neat categorization. This taxonomy matters because it converts a subjective visual impression, the kind that varies from one sonographer to the next, into discrete categories that can be compared, taught and audited. When the team cross-tabulated these patterns against final pathology, statistically significant differences emerged between benign salivary gland tumors and their malignant counterparts.

Two patterns stood out in opposite directions. Scattered microcalcifications predominated in benign tumors, a statistically significant association with a P value of 0.04, suggesting that fine, widely dispersed calcium specks are more a signature of slow-growing, well-behaved lesions than a warning sign. At the other extreme, irregular calcifications, labeled Type IV in the study’s scheme, were strongly associated with malignant salivary gland tumors, with a P value below 0.001. The biological logic is plausible: aggressive tumors outgrow their blood supply, producing internal necrosis and hemorrhage, and dystrophic calcification often deposits into that damaged tissue in haphazard, irregular forms. Malignant tissue also invades and disrupts architecture in ways that benign, encapsulated lesions do not, potentially explaining the chaotic deposit morphology.

The strongest result of the study came from multivariate analysis, the statistical step that asks which features independently predict malignancy once other variables are accounted for. Irregular calcifications emerged as the single strongest independent predictor of cancer, with an odds ratio of 29.4 and a 95 percent confidence interval spanning 4.751 to 181.626, at P below 0.001. In practical terms, a salivary gland tumor bearing irregular calcifications on ultrasound carries dramatically elevated odds of being malignant compared with one that lacks them. An odds ratio of that magnitude is rare in imaging research, where most sonographic features shift risk by factors of two or three, and it positions this single visual finding as a red flag that should reshape clinical decision-making the moment it appears on a scan.

Even more compelling is what happened when the researchers combined calcification pattern with another classic ultrasound feature: border definition. Tumors with ill-defined margins, meaning the lesion blends into surrounding tissue without a crisp capsule, are already regarded with suspicion. When the team built a diagnostic model pairing ill-defined borders with Type IV irregular calcifications, the model achieved an area under the receiver operating characteristic curve of 0.909, with sensitivity of 90.3 percent and specificity of 82.2 percent for detecting malignancy. An AUC above 0.9 is generally considered excellent discrimination, and the balance of sensitivity and specificity means the model catches the overwhelming majority of cancers while sparing most patients with benign disease from unnecessary alarm.

That balance matters because the stakes of salivary gland surgery are asymmetric. The standard treatment for a malignant parotid or submandibular tumor is wide surgical excision, often with sacrifice of facial nerve branches that run directly through the gland, since the facial nerve controls expression of the entire half of the face. Operating aggressively on every ambiguous lump would inflict facial weakness, numbness and Frey syndrome on many patients whose tumors were harmless. Conversely, under-treating a carcinoma ex pleomorphic adenoma or an adenoid cystic carcinoma, tumors known for perineural spread and late metastasis, can be catastrophic. A preoperative ultrasound sign that reliably separates the two populations gives surgeons and patients a much firmer footing for choosing the extent of surgery, whether to plan for nerve dissection, and how urgently to proceed.

The study’s design deserves scrutiny as well as its findings. Because it was retrospective and restricted to tumors that already showed calcifications on ultrasound, it cannot say how often calcifications occur across all salivary gland tumors, nor whether their absence is reassuring. Selection bias runs toward the diagnostically interesting cases: 104 calcified lesions out of the broader population of salivary tumors imaged at a high-volume hospital. The requirement for pathological confirmation in every case, however, means the gold standard diagnosis is solid, and the institutional review board of Shanghai Ninth People’s Hospital approved the protocol under the ethical principles of the Declaration of Helsinki, waiving individual informed consent given the retrospective design. The work was supported by research grants from the Fundamental Research Funds for the Central Universities, the Shanghai Municipal Health Commission’s clinical research program, and a subject group construction project at the hospital.

For the wider field, the study arrives amid a broader push to extract more diagnostic information from inexpensive, widely available imaging. Ultrasound is the first-line examination for salivary gland lumps almost everywhere in the world: it is fast, radiation-free, cheap and performed with handheld probes in outpatient clinics. Magnetic resonance imaging and computed tomography add detail but at far greater cost and access barriers, particularly in the low- and middle-income settings where head and neck cancer burdens are rising fastest. If a simple visual taxonomy of calcifications, teachable in an afternoon, can push ultrasound’s diagnostic accuracy toward the 0.9 AUC range, the practical impact could be substantial, triaging patients toward prompt surgery or confident observation without a single additional scan.

There is also a natural next step that the authors’ own institution hints at: machine learning. The journal’s related-subject suggestions pair this work with computational topics, and the four-category calcification scheme is exactly the kind of structured labeling that convolutional neural networks consume readily. A future system could flag irregular calcifications automatically on routine scans, standardizing what today depends on the trained eye of the individual sonologist. Until then, the message for clinicians reading an ultrasound report is concrete: when a salivary gland mass shows irregular, jagged calcifications, especially alongside blurred borders, that combination should be treated as a strong malignancy signal warranting definitive workup. And when the specks are fine and scattered, the findings lean reassuring, though pathology remains the final arbiter. What was once a footnote on an imaging report, the incidental bright dot, has now been promoted to a diagnostic sign with real predictive teeth.

Subject of Research: Ultrasound characterization of calcification patterns for differentiating benign from malignant primary salivary gland tumors

Article Title: Characteristics of ultrasound-based calcifications in primary salivary gland tumors

Article References: Ding, A., Cao, J., Lv, H., Zuo, J., Zhou, H., & Xiong, P. (2026). Characteristics of ultrasound-based calcifications in primary salivary gland tumors. BMC Cancer. https://doi.org/10.1186/s12885-026-17019-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17019-6

Keywords: salivary gland tumors, ultrasound, calcifications, malignancy prediction, microcalcifications, irregular calcifications, diagnostic model, differential diagnosis, head and neck oncology, medical imaging, odds ratio, BMC Cancer

Adenoid cystic carcinoma accounts for a considerable proportion of malignant neoplasms arising from the salivary glands, characterized by a propensity for perineural invasion and a typically dismal prognosis over extended follow-up periods. Conventional diagnostic algorithms heavily rely on histopathological evaluation supplemented by molecular assays targeting characteristic fusion genes. Historically, ACC is defined by the presence of MYB-NFIB or MYBL1-NFIB gene fusions, which serve as hallmark genetic events facilitating tumor identification. However, this new research underscores that such canonical genetic markers are not exhaustive, and alternative fusion gene configurations may be at play.

The patient in question presented with a relatively small, 1.7-centimeter tumor located on the palate, initially classified as a non-specific salivary gland neoplasm following routine histological assessment. It was only after the application of a comprehensive molecular panel that the tumor’s true identity as adenoid cystic carcinoma was elucidated. Remarkably, the panel returned negative results for the classical MYB::NFIB and MYBL1::NFIB fusion genes, challenging preconceived diagnostic parameters and underscoring the potential limitations of relying solely on traditional genetic indicators.

What the molecular analysis did reveal was the existence of a novel fusion gene, NFIB::PHACTR2, previously unreported in ACC pathology. This atypical genetic rearrangement links the NFIB gene — a frequent partner in ACC-associated fusions — with PHACTR2, a gene involved in actin regulation and cell signaling pathways. The identification of this fusion gene suggests that NFIB’s involvement remains a critical determinant in ACC oncogenesis, even beyond its fusion with MYB or MYBL1. This discovery broadens the spectrum of molecular alterations contributing to ACC and hints at a more complex genetic heterogeneity than previously appreciated.

Dr. Shuanzeng “Sam” Wei, MD, PhD, Associate Professor and Medical Director at Fox Chase’s Clinical Genomics Laboratory, highlights the clinical importance of this finding. “This case reveals a crucial diagnostic pitfall,” Dr. Wei explains. “The absence of the conventional MYB or MYBL1 fusions should not preclude a diagnosis of adenoid cystic carcinoma, especially in the presence of an NFIB fusion partner. Recognizing NFIB::PHACTR2 as a diagnostic marker can drastically improve diagnostic accuracy, particularly in unusual or ambiguous tumor presentations.”

From a clinical management standpoint, acknowledging this fusion gene’s role is vital in guiding surgical and therapeutic decision-making. ACC tumors exhibit a well-documented propensity to infiltrate neural structures, often necessitating radical excisions that include removal of affected nerves to achieve clear surgical margins. Misdiagnosis or delayed recognition may result in suboptimal surgery, incomplete tumor resection, and ultimately, poorer patient outcomes. Thus, molecular profiling emerges as a cornerstone of precision oncology, empowering clinicians to tailor interventions appropriately.

Moreover, this case exemplifies the burgeoning field of personalized medicine where molecular diagnostics not only inform prognosis but also open avenues for targeted therapies. While surgical resection remains the primary treatment modality, emerging molecular insights could facilitate the development of novel therapeutic agents targeting fusion-mediated oncogenic pathways. As researchers continue to unravel the functional consequences of NFIB::PHACTR2 and similar fusions, new pharmacologic vulnerabilities may be identified, offering hope for improved therapeutic efficacy in this challenging disease.

Despite these advances, molecular testing remains limited in accessibility, particularly outside of specialized cancer centers. Many smaller community hospitals may lack the resources or expertise to perform comprehensive genomic analyses, potentially hindering accurate tumor classification and optimal care. Dr. Wei advocates for referring complex or atypical cases to academic institutions or dedicated cancer centers equipped with state-of-the-art molecular diagnostics, ensuring patients receive the benefits of precise pathology and informed treatment planning.

The report, published in the April 2025 issue of Virchows Archiv— the prestigious journal of the European Society of Pathology—cements the role of advanced genomic techniques in contemporary oncology. It also serves as a clarion call to the pathology community to expand diagnostic panels and remain vigilant for novel fusion events that defy traditional paradigms. By disseminating such findings, the Fox Chase team aims to promote broader awareness among pathologists and oncologists worldwide.

In addition to its diagnostic value, the discovery of NFIB::PHACTR2 fosters a deeper understanding of ACC’s molecular biology. NFIB’s recurring involvement as a fusion partner underscores its centrality in tumorigenesis. PHACTR2, meanwhile, although less characterized, is implicated in actin cytoskeleton modulation and intracellular signaling, processes integral to cellular motility and invasion—hallmarks of ACC’s aggressive phenotype. This fusion may contribute to the invasive capabilities of ACC, warranting further functional studies to elucidate its oncogenic mechanisms.

The implications extend beyond just a single tumor type: this case exemplifies the evolving concept that cancer biology is governed by a constellation of genetic aberrations, often context-dependent and variable across patients. As sequencing technologies become more sophisticated and cost-effective, the identification of novel driver mutations and fusion genes will increasingly refine cancer diagnosis and therapy. This molecular granularity underpins the shift towards truly individualized oncology, where the molecular signatures of tumors dictate clinical management.

Ultimately, this groundbreaking research highlights that while traditional markers remain indispensable, the landscape of cancer diagnostics is expanding. Recognizing atypical genetic alterations like NFIB::PHACTR2 fusion empowers clinicians to avoid diagnostic pitfalls and optimize patient care. It reaffirms the necessity for integrating comprehensive molecular testing into the diagnostic workflow of salivary gland neoplasms, especially when conventional markers are absent. This integration promises to enhance prognostication, tailor therapeutic approaches, and potentially improve survival outcomes for patients facing this formidable disease.

As molecular medicine advances at an unprecedented pace, discoveries like this emphasize that cancer is not a monolithic entity but a highly heterogeneous constellation of diseases. Continued investment in molecular pathology and collaborative research endeavors remain pivotal in unraveling these complexities, ultimately translating genomic insights into meaningful clinical benefits. The Fox Chase Cancer Center’s contribution thus marks a significant milestone in the relentless quest to decode and defeat adenoid cystic carcinoma.

Subject of Research: People
Article Title: NFIB::PHACTR2, a novel atypical fusion gene identified in adenoid cystic carcinoma of the palate
News Publication Date: 21-Apr-2025
Web References: 10.1007/s00428-025-04107-4
References: Virchows Archiv, European Society of Pathology
Keywords: Cancer; Mouth; Salivary glands